Survodutide, a novel glucagon/GLP-1 receptor dual agonist, improved metabolic dysfunction-associated steatohepatitis (MASH) ...

PBC is a rare, chronic cholestatic liver disease that left untreated can progress to cirrhosis, require liver transplantation ...

Ipsen will charge $11,500 for a month’s supply of the first-in-class peroxisome proliferator-activated receptor (PPAR) ...

Iqirvo, an oral dual peroxisome proliferator–activated receptor (PPAR) alpha and delta agonist, is the first new drug ...

Both studies met their primary and secondary endpoints. GSBR-1290 is a highly selective oral GLP-1 receptor agonist, being ...

Bariatric metabolic surgery (BMS) is associated with a greater reduction in mortality than glucagon-like peptide-1 receptor ...

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability ...

and inventor of the Dual Orexin Receptor Agonist platform (DOXA). "This application highlights the continued commitment from NLS to pioneer therapeutic approaches to address significant unmet medical ...

An experimental 'supercharged' form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial ...

Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

Patients with heart failure and preserved ejection fraction have symptomatic and functional improvements with semaglutide ...

IGC Pharma, Inc. announced the publication of groundbreaking research in the European Society of Medicine Journal.